查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1628000

GLP-1受体激动剂市场机会、成长动力、产业趋势分析及2024年至2032年预测

GLP-1 Receptor Agonist Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球GLP-1受体激动剂市场达到244亿美元，预计2024年至2032年复合年增长率为9.7%。的。根据最近的研究，未来几十年，糖尿病患者数量预计将增加一倍以上，这凸显了对有效治疗方案的迫切需求。

GLP-1 受体激动剂因其在控制第 2 型糖尿病和促进减肥方面的双重功效而获得了巨大的关注。这些药物模仿天然肠促胰岛素激素来调节血糖水平，同时帮助控制体重，并解决两个关键的健康挑战。随着医疗保健提供者和患者寻求副作用最小的有效疗法，对 GLP-1 受体激动剂的需求预计将急剧上升。药物配方的进步和这些治疗方法已被证实的益处正在进一步推动市场扩张。

依给药途径，市场分为肠胃外和口服两类。以注射剂型为主的注射剂细分市场在2023 年占据了最大的市场份额，预计到2032 年将保持领先地位。青睐，使其成为管理疾病的可靠选择。儘管口服替代品不断涌现，但注射剂因其良好的临床成功和稳定的剂量能力而占据主导地位。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 244亿美元
预测值 557 亿美元
复合年增长率 9.7%

市场按应用进一步分为第 2 型糖尿病、肥胖症和其他用途。 2 型糖尿病细分市场在 2023 年占据最大份额，预计将经历强劲成长。作为全球最普遍的慢性疾病之一，2 型糖尿病迫切需要有效的管理解决方案。 GLP-1 受体激动剂提供了一种创新方法，可提供血糖控制、体重管理的益处，满足糖尿病护理的关键需求。

北美 GLP-1 受体激动剂市场预计到 2032 年将大幅成长。美国因其先进的医疗保健生态系统、大量的医药投资以及创新疗法而脱颖而出。这些因素使北美成为全球 GLP-1 受体激动剂市场的关键驱动力。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 糖尿病和肥胖等慢性疾病的盛行率不断上升
      • 增加研发活动以开发新疗法
      • 口服GLP-1受体激动剂的製剂进展
      • 提高对糖尿病诊断和治疗方案的认识
    • 产业陷阱与挑战
      • 与少数 GLP-1 激动剂药物相关的不良反应
      • 市场参与者召回产品
  • 成长潜力分析
  • 临床试验分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 全球公司市占率分析
  • 竞争定位矩阵
  • 战略仪錶板

第 5 章：市场估计与预测：按药物类别

  • 主要趋势
  • 索马鲁肽
  • 度拉鲁肽
  • 利拉鲁肽
  • 艾塞那肽
  • 其他药物类别

第 6 章：市场估计与预测：按给药途径

  • 主要趋势
  • 注射用
  • 口服

第 7 章：市场估计与预测：按应用

  • 主要趋势
  • 2型糖尿病
  • 肥胖
  • 其他应用

第 8 章：市场估计与预测：按配销通路

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 瑞士
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 10 章：公司简介

  • Eli Lilly and Company
  • Sanofi
  • Novo-Nordisk A/S
  • AstraZeneca
  • Pfizer, Inc.
  • Amgen, Inc.
  • Innovent Biologics, Inc.
  • PegBio Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
简介目录
Product Code: 5864

The Global GLP-1 Receptor Agonist Market reached USD 24.4 billion in 2023 and is projected to grow at a CAGR of 9.7% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of type 2 diabetes and obesity worldwide. According to recent research, the number of individuals living with diabetes is expected to more than double in the coming decades, highlighting the urgent need for effective treatment options.

GLP-1 receptor agonists have gained significant traction due to their dual efficacy in managing type 2 diabetes and promoting weight loss. These drugs mimic natural incretin hormones to regulate blood sugar levels while aiding in weight management, addressing two critical health challenges. As healthcare providers and patients seek effective therapies with minimal side effects, the demand for GLP-1 receptor agonists is expected to rise sharply. Advancements in drug formulations and the proven benefits of these treatments are further fueling market expansion.

By route of administration, the market is segmented into parenteral and oral categories. The parenteral segment, dominated by injectable formulations, accounted for the largest market share in 2023 and is anticipated to maintain its lead through 2032. Injectable GLP-1 receptor agonists are favored for their superior bioavailability and consistent efficacy, making them a reliable choice for managing diabetes and obesity. Although oral alternatives are emerging, injectables dominate due to their well-established clinical success and stable dosing capabilities.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$24.4 Billion
Forecast Value$55.7 Billion
CAGR9.7%

The market is further divided by application into type 2 diabetes, obesity, and other uses. The type 2 diabetes segment held the largest share in 2023 and is expected to experience robust growth. As one of the most widespread chronic diseases globally, type 2 diabetes drives a significant need for efficient management solutions. GLP-1 receptor agonists provide an innovative approach by offering glycemic control weight management benefits, addressing a critical need in diabetes care.

North America GLP-1 receptor agonist market is set to grow substantially through 2032. High diabetes and obesity rates, combined with a strong healthcare infrastructure, contribute to the region's dominance. The United States stands out due to its advanced healthcare ecosystem, significant pharmaceutical investments, and access to innovative treatments. These factors position North America as a key driver of the global GLP-1 receptor agonist market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases such as diabetes and obesity
      • 3.2.1.2 Increasing R&D activities for developing novel therapeutics
      • 3.2.1.3 Formulation advancements of oral GLP-1 receptor agonists
      • 3.2.1.4 Increasing awareness about diagnosis and treatment options for diabetes
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with few GLP-1 agonist drugs
      • 3.2.2.2 Product recalls by market players
  • 3.3 Growth potential analysis
    • 3.3.1 By drug class
    • 3.3.2 By route of administration
    • 3.3.3 By application
    • 3.3.4 By distribution channel
  • 3.4 Clinical trial analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Global company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million)

  • 5.1 Key trends
  • 5.2 Semaglutide
  • 5.3 Dulaglutide
  • 5.4 Liraglutide
  • 5.5 Exenatide
  • 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million)

  • 6.1 Key trends
  • 6.2 Parenteral
  • 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Application (USD Million)

  • 7.1 Key trends
  • 7.2 Type 2 diabetes mellitus
  • 7.3 Obesity
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region (USD Million)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Switzerland
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Eli Lilly and Company
  • 10.2 Sanofi
  • 10.3 Novo-Nordisk A/S
  • 10.4 AstraZeneca
  • 10.5 Pfizer, Inc.
  • 10.6 Amgen, Inc.
  • 10.7 Innovent Biologics, Inc.
  • 10.8 PegBio Co., Ltd.
  • 10.9 Sun Pharmaceutical Industries Ltd.
  • 10.10 Boehringer Ingelheim International GmbH